the reason I asked that question is because, the f
Post# of 148190
Quote:
the reason I asked that question is because, the fda will be receiving all that data when they go to assess leronlimab for safety. will the fda also go on to assess leronlimab for effectiveness with that data?
The FDA will only get the data regarding safety. Even if they were to receive efficacy data the FDA would not express an opinion on efficacy without a BLA submission.